Mesoblast Ltd.
๐ฆ๐บAustralia
- Country
- ๐ฆ๐บAustralia
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 73
- Market Cap
- -
- Website
- http://www.mesoblast.com
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion
Phase 2
Completed
- Conditions
- Degenerative Disc DiseaseDegenerative SpondylolisthesisSpinal Stenosis
- Interventions
- Biological: Lumbar Interbody Fusion with NeoFuseBiological: Lumbar Interbody Fusion with Autograft
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT00996073
- Locations
- ๐บ๐ธ
The Spine Institute, Santa Monica, California, United States
๐บ๐ธDenver Spine, Greenwood Village, Colorado, United States
๐บ๐ธRocky Mountain Associates in Orthopedic Medicine, P.C., Loveland, Colorado, United States
Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion
Phase 1
Withdrawn
- Conditions
- Degenerative SpondylolisthesisSpinal StenosisDegenerative Disc Disease
- Interventions
- Biological: PLF with NeoFuseProcedure: PLF with autograft
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Mesoblast, Ltd.
- Registration Number
- NCT00810212
- Locations
- ๐บ๐ธ
Texas Back Institute, Plano, Texas, United States
A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure
Phase 2
Completed
- Conditions
- Heart Failure
- Interventions
- Biological: Mesenchymal Precursor Cells (MPCs)Procedure: standard-of-care treatment with mock mapping and injection procedures.
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT00721045
- Locations
- ๐บ๐ธ
Mercy Gilbert Medical Center, Gilbert, Arizona, United States
๐บ๐ธUniversity of California, San Diego, La Jolla, California, United States
๐บ๐ธMinneapolis Heart Institute 920 East 28th St, Suite 300, Minneapolis, Minnesota, United States
Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)
Phase 1
Completed
- Conditions
- Degenerative Disc DiseaseSpinal StenosisSpondylolisthesis
- Interventions
- Biological: NeoFuseProcedure: posterolateral spinal fusion with instrumentation
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Mesoblast, Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT00549913
- Locations
- ๐บ๐ธ
Hospital for Special Surgery, New York, New York, United States